The CND Life Sciences funding will support the commercial expansion and innovation of a skin biopsy-based test used in evaluating REM sleep behavior disorder and other synucleinopathies.

Significant changes to unattended sleep testing coding are on the horizon, making now the perfect time for practices to prepare. At Business of Sleep Medicine, attendees can join the session “Updates in Sleep Medicine Bi...

A newly developed foundation model analyzes standard polysomnogram data to identify patient groups with varying long-term health risks.

A new Swiss study reveals how the brain reorganizes sensory processing as it shifts into REM sleep, turning its listening inward to preserve cardiac signals.

On Aug. 5, 2026, Takeda announced that the U.S. Food and Drug Administration approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. Orzeyful is the first medicine approved to treat narc...

The federal agency accepted a new drug application for AXS-12, an investigational treatment for cataplexy in narcolepsy.

The long-time patient advocate steps into the leadership role to continue advancing education, support, and research for the sleep disorder community.

DarioHealth has expanded its cardiometabolic care platform with two new programs designed to address obstructive sleep apnea and menopause-related sleep disruptions. Slated for a fall 2026 enterprise rollout, the integra...

Scientists expected these neurons to regulate REM sleep. Instead, they found the cells abruptly promote non-REM sleep and trigger sleep attacks in a mouse model of narcolepsy.

It is the first approved medication that directly restores orexin signaling to treat the full range of symptoms associated with NT1.